Saturday 17 October 2026
Export VKTX’s income statement to Excel — free account
Viking Therapeutics, Inc.
VKTX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 89.7% and free cash flow fell 166.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
25.17
2.20
−8.04%
Follow VKTX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 0.90 | 0.88 | 3.69 | 6.15 | 3.26 | 4.41 | 2.02 | 7.97 | 17.23 | 18.92 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 4.24 | 4.40 | 24.00 | 11.03 | 8.36 | 10.09 | 9.62 | 25.72 | 99.41 | 43.55 | |||||
| People | |||||||||||||||
| People | Employees | 12 | 14 | 18 | 16 | 20 | 18 | 21 | 27 | 36 | 53 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (15) | (21) | (22) | (26) | (39) | (55) | (69) | (86) | (110) | (360) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (15) | (21) | (22) | (26) | (39) | (55) | (69) | (86) | (110) | (360) | |||||
| Depreciation | 2 | 3 | 1 | 1 | 4 | 4 | 2 | (8) | (17) | (9) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (0.90) | (0.79) | (0.38) | (0.36) | (0.54) | (0.71) | (0.90) | (0.91) | (1.01) | (3.19) | |||||
| Cash flow | (0.68) | (0.57) | (0.33) | (0.34) | (0.30) | (0.62) | (0.63) | (0.78) | (0.81) | (2.47) | |||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (0.68) | (0.57) | (0.33) | (0.34) | (0.30) | (0.62) | (0.63) | (0.78) | (0.81) | (2.47) | |||||
| Book value | 0.49 | 0.52 | 5.17 | 3.85 | 3.37 | 2.62 | 1.89 | 3.69 | 8.07 | 5.67 | |||||
| Shares, m | 16 | 26 | 58 | 72 | 73 | 77 | 77 | 94 | 109 | 113 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (11) | (15) | (19) | (25) | (22) | (48) | (48) | (73) | (88) | (279) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | (11) | (15) | (19) | (25) | (22) | (48) | (48) | (73) | (88) | (279) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 7 | 13 | 298 | 277 | 244 | 202 | 145 | 348 | 880 | 639 | ||||
| Total debt | 3 | 3 | — | 1 | 0 | 0 | 2 | — | — | — | |||||
| Net debt | (10) | (17) | (302) | (276) | (248) | (202) | (155) | (362) | (903) | (706) | |||||
| Shareholders’ equity | 8 | 13 | 298 | 277 | 244 | 202 | 145 | 348 | 880 | 639 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (98.29) | (112.27) | (13.60) | (8.79) | (14.61) | (23.54) | (36.32) | (31.99) | (17.22) | (44.29) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | (1,379.43) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (175.71) | (191.36) | (14.18) | (8.97) | (15.15) | (24.65) | (39.67) | (34.79) | (17.90) | (47.34) | |||||
Negative figures in brackets.
Charts ten years each
Viking Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics, Inc. | $3.8B | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −4.58% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RLAY Relay Therapeutics, Inc. | $3.8B | — (loss-making) | — (loss-making) | −95.44% (below 0%: shrinking) | n/m | +2.13% (above 0%: growing) | 100.00% | (25,949.71%) | Compare |
| ARQT Arcutis Biotherapeutics, Inc. | $3.7B | 131× | 196× | +59.33% (above 0%: growing) | n/m | +227.96% (above 0%: growing) | 91.58% | 12.65% | Compare |
| TLX Telix Pharmaceuticals Limited | $3.6B | — | — | — | — | −44.78% (below 0%: shrinking) | — | — | Compare |
| TARS Tarsus Pharmaceuticals, Inc. | $3.5B | — (loss-making) | — (loss-making) | +69.41% (above 0%: growing) | n/m | +288.08% (above 0%: growing) | 93.03% | (11.45%) | Compare |
| VKTX Viking Therapeutics, Inc. | $3.5B | — (loss-making) | — | — | n/m | −165.98% (below 0%: shrinking) | 0.00% | 0.00% | |
| ACAD ACADIA Pharmaceuticals Inc. | $3.4B | 8.5× | 55.6× | +16.40% (above 0%: growing) | +12.50% (above 0%: growing) | +50.32% (above 0%: growing) | 90.81% | 12.29% | Compare |
| XENE Xenon Pharmaceuticals Inc. | $3.3B | — (loss-making) | — (loss-making) | +100.70% (above 0%: growing) | n/m | −48.57% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IDYA IDEAYA Biosciences, Inc. | $3.3B | — (loss-making) | — (loss-making) | +125.77% (above 0%: growing) | n/m | −41.09% (below 0%: shrinking) | 100.00% | (1,380.73%) | Compare |
| Median of peers | $3.6B | — | — | +59.33% | — | −1.22% | 93.03% | 0.00% |
Viking Therapeutics, Inc. (VKTX) key facts
- Viking Therapeutics, Inc. (VKTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, VKTX traded at $25.17, a market capitalization of $3.5 billion.
- Return on equity was −47.3% and debt-to-equity 0.00.